Eight Generic Companies Agree Not to Sell Cymbalta Copies Before Lilly Patent Expires

Eight generic drug companies April 26 agreed they would not seek to market generic copies of Eli Lilly and Co.'s antidepressant Cymbalta (duloxetine HCl oral capsules) before a patent on the drug expires, according to orders entered in federal court in Indianapolis (Eli Lilly and Co. v. Wockhardt Ltd.).

Judge Tanya Walton Pratt of the U.S. District Court for the Southern District of Indiana entered separate orders barring each of the eight companies—including Anchen Pharmaceuticals Inc., Actavis Elizabeth LLC, Aurobindo Pharma Ltd., Cobalt Laboratories Inc., Impax Laboratories Inc., Lupin Ltd., Sandoz Inc., and Sun Pharmaceutical Industries Ltd.—from marketing ...